European Patients Forum, logo.

EUP OHAMR

Project information 

Full title: European Partnership One Health Antimicrobial Resistance (EUP OHAMR)

Duration: 120 months (June 2025 to May 2034)

Status: Ongoing 

Funding programme: Horizon Europe, HORIZON-HLTH-2024-DISEASE-09-01 – HORIZON-COFUND Action

What will the project do? 

Antimicrobial resistance (AMR) is a growing global threat, with a projected 67% increase in deaths due to AMR by 2050. The EUP OHAMR partnership adopts a One Health approach, recognising the interconnections between human, animal, and environmental health.
 
This co-funded partnership will strengthen research and innovation across sectors by addressing:
  • Surveillance of resistant pathogens,
  • Diagnostics and treatment of drug-resistant infections,
  • Prevention strategies to reduce antimicrobial use and spread of AMR,
  • Coordination of R&I investments,
  • Knowledge translation into policies and practice.
The partnership expands upon previous efforts under the Joint Programming Initiative on AMR, aiming for broader scope and impact.
 

What are the expected outcomes? 

  • Boosting AMR R&I: Closing knowledge gaps and fostering innovation in diagnostics, surveillance, and therapeutic solutions.
  • Multisectoral alignment: Harmonising national and EU-level policies, priorities, and investments.
  • Effective translation: Ensuring uptake of research results by industry, policymakers, and civil society.
  • Stronger ecosystem: Supporting capacity building, data use/reuse, and the breaking of silos between disciplines.
  • Policy impact: Contributing to the European One Health Action Plan against AMR and reinforcing the European Research and Innovation Area (ERA).

What is EPFs’ role? 

The European Patients’ Forum (EPF) is listed among the project’s 50 partners. As a civil society representative, EPF contributes to:
  • Promoting engagement of patients and the public in AMR-related research and policy,
  • Supporting dissemination and outreach activities,
  • Providing input to ensure inclusive, patient-centred approaches within the partnership’s design and implementation.

The consortium 

The EUP OHAMR consortium is led by the Swedish Research Council (VETENSKAPSRADET) and consists of 50 partners from 28 countries (including EU and associated/non-EU countries). It brings together: